Kyverna Therapeutics, Inc. ( (KYTX) ) has released its Q3 earnings. Here is a breakdown of the information Kyverna Therapeutics, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with its lead product candidate, KYV-101, in late-stage clinical development. In its latest earnings report, the company highlighted a significant net loss of $123.5 million for the nine months ended September 30, 2025, compared to a $90.0 million loss in the same period in 2024. The company’s financial performance was marked by a decrease in cash and cash equivalents to $34.2 million from $96.6 million at the end of 2024, alongside a reduction in total assets from $304.6 million to $187.2 million. Operating expenses rose to $130.5 million, primarily driven by increased research and development costs. Despite these challenges, Kyverna continues to focus on advancing its product pipeline and securing additional funding. Looking ahead, the company remains committed to its strategic goals, with management estimating that existing financial resources will support operations for at least the next 12 months.